Harm reduction is a public health approach that reduces the negative consequences of substance use without requiring abstinence. Pharmacological literacy — understanding how drugs work, how the body processes them, and what makes some patterns of use more dangerous than others — is essential infrastructure for harm reduction practice. This text connects pharmacological concepts to harm reduction applications.
Overdose prevention: the pharmacology
Overdose is not a moral failure. It is a pharmacological event with identifiable mechanisms and preventable causes.
Opioid overdose kills through respiratory depression. Mu-opioid receptors in the brainstem respiratory centers, when activated beyond a threshold, suppress the drive to breathe. The patient becomes hypoxic, loses consciousness, and — without intervention — dies. The mechanism is dose-dependent: higher receptor occupancy produces greater respiratory depression. But the lethal dose varies dramatically between individuals based on:
- Tolerance — a tolerant person can survive doses that would kill an opioid-naive person. But tolerance is lost rapidly (days to weeks of reduced use), and the dose that was tolerated before a period of abstinence may be lethal afterward. This is the primary mechanism of post-incarceration overdose death.
- Drug interactions — benzodiazepines, alcohol, and other CNS depressants act synergistically with opioids on respiratory depression. The combination is more dangerous than the sum of the individual drugs.
- Route of administration — injection and smoking bypass first-pass metabolism, producing higher peak plasma concentrations and faster onset than oral use. The same amount of drug produces different peak concentrations — and different overdose risk — depending on route.
- Supply variability — when the drug supply contains fentanyl (50-100x more potent than heroin) or its analogues (carfentanil is roughly 10,000x more potent), users who dose based on heroin expectations receive a pharmacologically different drug. This is not a user error. It is a supply-side problem that no amount of individual caution can fully address.
Naloxone reverses opioid overdose through competitive antagonism: it binds to mu-opioid receptors with higher affinity than most opioids, displacing them and reversing respiratory depression. It has a wide therapeutic index — effective doses are far below toxic doses — and minimal effect in people who have not taken opioids. This pharmacological profile is what makes community naloxone distribution rational: the benefit is life-saving, the risk is negligible, and the required pharmacological knowledge for administration is minimal.
The limitation of naloxone is its half-life — approximately 30-90 minutes, shorter than most opioids. A patient revived by naloxone can re-enter overdose as the naloxone wears off while the opioid remains active. This is why naloxone administration should be followed by monitoring and, in many cases, repeat dosing.
Opioid agonist therapy: the pharmacology
Methadone and buprenorphine are the pharmacological foundations of opioid use disorder treatment. Their effectiveness is explained by their pharmacodynamic and pharmacokinetic properties:
Methadone — a full mu-opioid agonist with a long half-life (24-36 hours). The long half-life provides stable receptor occupancy throughout the day, preventing the peaks and troughs that drive compulsive dosing of short-acting opioids. The patient experiences neither euphoria (because the slow onset and steady state prevent the rapid receptor activation that produces the “high”) nor withdrawal (because the receptors remain occupied). The risk is that methadone, as a full agonist, retains the capacity for respiratory depression — overdose is possible, particularly during dose initiation.
Buprenorphine — a partial mu-opioid agonist with a long half-life (24-60 hours). The partial agonism provides a ceiling effect: beyond a certain dose, additional buprenorphine does not increase the effect. This ceiling applies to both the therapeutic effect and respiratory depression, making buprenorphine substantially safer than methadone in overdose. The long half-life provides the same steady-state stability as methadone. Buprenorphine also has high receptor affinity, meaning it can displace other opioids from the receptor — which is why it must be initiated carefully in opioid-dependent patients (precipitated withdrawal can occur if buprenorphine displaces a full agonist while the patient is still in an agonist-dependent state).
Both medications reduce mortality, reduce illicit opioid use, reduce criminal involvement, improve social functioning, and reduce HIV and hepatitis C transmission. They are not “replacing one addiction with another.” They are pharmacological interventions that stabilize a dysfunctional neurobiological system — just as insulin stabilizes a dysfunctional metabolic system in diabetes.
Safe supply and drug checking: the pharmacology
Safe supply programs provide pharmaceutical-grade substances of known potency and purity to people who would otherwise use illicit drugs of unknown composition. The pharmacological rationale:
- Known potency allows accurate dosing. The primary overdose risk from the illicit supply is not that people use too much — it is that they cannot know how much they are using because the potency is unknown.
- Known purity eliminates adulterants and contaminants that produce additional toxicity beyond the intended drug’s effects.
- Pharmaceutical-grade formulation provides predictable bioavailability, eliminating the pharmacokinetic variability that comes from inconsistent illicit drug preparation.
Drug checking services (where people can test their substances for composition and potency) provide a partial version of this information. Fentanyl test strips, mass spectrometry analysis, and other technologies allow users to know what they are about to take — which allows them to adjust dosing, avoid dangerous adulterants, or choose not to use a particular sample.
The political dimension
Pharmacological literacy is not politically neutral. The knowledge that makes harm reduction possible — understanding dose-response, tolerance, drug interactions, overdose mechanisms, and agonist therapy — is the same knowledge that the “war on drugs” framework treats as unnecessary or dangerous. The immunitarian logic of drug prohibition says: don’t use drugs, and you won’t need to understand how they work. The communitarian logic of harm reduction says: people do use drugs, and pharmacological knowledge is part of the infrastructure that keeps them alive.
Disability justice extends this analysis. Many people who use illicit drugs are self-medicating chronic pain, trauma, mental illness, or the physiological effects of poverty and discrimination. The pharmacological solutions available to them through the medical system are often inadequate (undertreated pain), inaccessible (insurance barriers, prescriber reluctance), or harmful (forced tapers, criminalizing prescribing patterns). Harm reduction pharmacology treats the situation as it is, not as it should be.